Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 6/20 | 0.52 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.39 |
| ▸ | LAP3 | P28838 | 1/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | PGK2 | P07205 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4819680 | 0.79 | BTN3A1 (0.38) | FDPSBTN3A1LAP3PGK1PGK2 | |
| SCHEMBL9176133 | 0.78 | FDPS (0.54) | FDPS | |
| SCHEMBL28028382 | 0.75 | FDPS (0.44) | FDPSBTN3A1LAP3PGK1PGK2 | |
| SCHEMBL10785210 | 0.73 | FDPS (0.67) | FDPS | |
| SCHEMBL2454026 | 0.72 | — | — | |
| SCHEMBL1850194 | 0.70 | FOLH1 (0.60) | FDPS | |
| SCHEMBL4095556 | 0.69 | FDPS (1.00) | FDPSLAP3 | |
| SCHEMBL16527330 | 0.69 | FDPS (0.55) | FDPSLAP3PGK1PGK2 | |
| SCHEMBL2454398 | 0.68 | TYMS (0.52) | BTN3A1 | |
| SCHEMBL9175678 | 0.68 | FDPS (0.48) | FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009123-A1 | Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2004-01-15 | — | — | US | claimed |
| US-20040006131-A1 | Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2004-01-08 | — | — | US | claimed |
| US-6624151-B1 | Concerns the uses of said compounds as selective inhibitors of T gamma 9 delta 2 lymphocytes, their uses, for therapeutic purposes. | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2003-09-23 | — | — | US | claimed |
| EP-1165573-A1 | COMPOUNDS SELECTIVELY INHIBITING GAMMA 9 DELTA 2 T LYMPHOCYTES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-01-02 | — | — | EP | claimed |
| WO-2000059916-A1 | COMPOUNDS SELECTIVELY INHIBITING GAMMA 9 DELTA 2 T LYMPHOCYTES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2000-10-12 | — | — | WO | claimed |
| EP-1165573-B1 | COMPOUNDS SELECTIVELY INHIBITING GAMMA 9 DELTA 2 T LYMPHOCYTES | INST NAT SANTE ETDE LA RECH ME (FR) | 2004-01-21 | — | — | EP | disclosed |
| US-20040009123-A1 | Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2004-01-15 | — | — | US | disclosed |
| US-20040006131-A1 | Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2004-01-08 | — | — | US | disclosed |
| US-6624151-B1 | Concerns the uses of said compounds as selective inhibitors of T gamma 9 delta 2 lymphocytes, their uses, for therapeutic purposes. | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2003-09-23 | — | — | US | disclosed |
| EP-1165573-A1 | COMPOUNDS SELECTIVELY INHIBITING GAMMA 9 DELTA 2 T LYMPHOCYTES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059916-A1 | COMPOUNDS SELECTIVELY INHIBITING GAMMA 9 DELTA 2 T LYMPHOCYTES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006131-A1 | Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes | CD4, IL2RA, CD74 | FDPS 2429/4885BTN3A1 947/4885LAP3 3143/4885 |
| US-20040009123-A1 | Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes | CD4, IL2RA, CD74 | FDPS 2429/4885BTN3A1 947/4885LAP3 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.